The effect of N-acetylcysteine on metabolic dysfunction associated with fatty liver disease and polycystic ovary syndrome as metabolic disorders
Ramadan, A., Abdel Wahab, M., El Wakeel, L., Fahmy, S. (2025). The effect of N-acetylcysteine on metabolic dysfunction associated with fatty liver disease and polycystic ovary syndrome as metabolic disorders. EKB Journal Management System, 9(1), 36-51. doi: 10.21608/aps.2024.331488.1205
Asmaa M. Ramadan; Mohamed Abdel Wahab; Lamia El Wakeel; Sarah F Fahmy. "The effect of N-acetylcysteine on metabolic dysfunction associated with fatty liver disease and polycystic ovary syndrome as metabolic disorders". EKB Journal Management System, 9, 1, 2025, 36-51. doi: 10.21608/aps.2024.331488.1205
Ramadan, A., Abdel Wahab, M., El Wakeel, L., Fahmy, S. (2025). 'The effect of N-acetylcysteine on metabolic dysfunction associated with fatty liver disease and polycystic ovary syndrome as metabolic disorders', EKB Journal Management System, 9(1), pp. 36-51. doi: 10.21608/aps.2024.331488.1205
Ramadan, A., Abdel Wahab, M., El Wakeel, L., Fahmy, S. The effect of N-acetylcysteine on metabolic dysfunction associated with fatty liver disease and polycystic ovary syndrome as metabolic disorders. EKB Journal Management System, 2025; 9(1): 36-51. doi: 10.21608/aps.2024.331488.1205

The effect of N-acetylcysteine on metabolic dysfunction associated with fatty liver disease and polycystic ovary syndrome as metabolic disorders

Archives of Pharmaceutical Sciences Ain Shams University
Article 3, Volume 9, Issue 1, June 2025, Page 36-51  XML PDF (654.02 K)
Document Type: Review Article
DOI: 10.21608/aps.2024.331488.1205
View on SCiNiTO View on SCiNiTO
Authors
Asmaa M. Ramadan email 1; Mohamed Abdel Wahab2; Lamia El Wakeelorcid 3; Sarah F Fahmyorcid 3
1Dar El-Salam Cancer Center, Cairo, Egypt
2Department of Liver Transplantation, National Hepatology and Tropical Research Institute, Cairo, Egypt
3Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt
Abstract
Metabolic dysfunction associated with fatty liver disease (MAFLD) and polycystic ovary syndrome (PCOS) are common disorders often related to metabolic syndrome. Insulin resistance, obesity, and oxidative stress contribute to the pathogenesis of both MAFLD and PCOS.
N-acetyl cysteine (NAC) is an antioxidant with anti-inflammatory, antiapoptotic, and insulin-sensitizing properties, and arises as a possible therapeutic option for MAFLD and PCOS. This review aims to investigate the effect of NAC alone or in combination on the metabolic parameters associated with MAFLD and PCOS. Using pre-defined keywords, PubMed, Google Scholar, and clinical trial.gov were systemically searched to identify related studies. A total of 10 studies related to MAFLD and 17 other studies related to PCOS were included. In conclusion, most of the included studies showed a promising impact of NAC in reducing elevated transaminases and the degree of liver steatosis in MAFLD through reducing oxidative stress and insulin resistance. Regarding PCOS, NAC was reported to have a positive effect on endometrial thickness, ovulation rate, and pregnancy rate either alone or when combined with clomiphene citrate. Further clinical trials are needed to confirm these results. 
Keywords
N-acetyl cysteine; metabolic syndrome; non-alcoholic fatty liver; metabolic dysfunction associated with fatty liver; polycystic ovary syndrome
Statistics
Article View: 230
PDF Download: 87